Merus (MRUS) PT Doubled to $32 at Wedbush Amid Incyte Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Citi Upgrades Merus N.V. (MRUS) to Buy
December 22, 2016 7:40 AM ESTCiti upgraded Merus N.V. (NASDAQ: MRUS) from Neutral to Buy with a price target of $26.00 (from $19.00), citing transformational Incyte deal.
Analyst Yigal Nochomovitz notes highlights of the deal are: 1) platform-based agreement for Merus' bispecific antibodies involving up to 11 preclinical programs (excludes clinical... More
Merus N.V. (MRUS) Surges 50% on Incyte (INCY) Collaboration
December 21, 2016 8:15 AM ESTMerus N.V. (NASDAQ: MRUS) surges 51% in pre-open trade after the company and Incyte Corporation (NASDAQ: INCY) entered into a global,... More
Merus N.V. (MRUS) and Incyte (INCY) Announce Research Collaboration
December 21, 2016 7:02 AM ESTIncyte Corporation (NASDAQ: INCY) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a global, strategic collaboration agreement focused on the research, discovery and development of bispecific antibodies utilizing Merus proprietary Biclonics® technology platform. The Collaboration and License Agreement grants Incyte the exclusive rights for up to eleven bispecific antibody research programs, including two of Merus current preclinical immuno-oncology discovery programs.
Biclonics® retain the IgG format of antibodies that are produced naturally by the immune system and, by binding to two targets, enable multiple modes of... More
